| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A fixed-duration, measurable residual disease–guided approach in CLL: follow-up data from the phase 2 ICLL-07 FILO trial
|
Michallet, Anne-Sophie
|
|
|
137 |
8 |
p. 1019-1023
|
artikel
|
| 2 |
Another front in COVID-19's perfect storm
|
Jobe, Shawn M.
|
|
|
137 |
8 |
p. 1006-1007
|
artikel
|
| 3 |
Antibody-induced procoagulant platelets in severe COVID-19 infection
|
Althaus, Karina
|
|
|
137 |
8 |
p. 1061-1071
|
artikel
|
| 4 |
A prospective, blinded study of a PF4-dependent assay for HIT diagnosis
|
Samuelson Bannow, Bethany
|
|
|
137 |
8 |
p. 1082-1089
|
artikel
|
| 5 |
Autoimmune hemolytic anemia complicated by parvovirus infection
|
Wachter, Franziska
|
|
|
137 |
8 |
p. 1130
|
artikel
|
| 6 |
A wave of bipotent T/ILC-restricted progenitors shapes the embryonic thymus microenvironment in a time-dependent manner
|
Elsaid, Ramy
|
|
|
137 |
8 |
p. 1024-1036
|
artikel
|
| 7 |
Can HIT testing lose its radioactivity?
|
Lee, Grace M.
|
|
|
137 |
8 |
p. 1008-1010
|
artikel
|
| 8 |
CAR-T treatment of pediatric AML: a long and winding road
|
De Moerloose, Barbara
|
|
|
137 |
8 |
p. 1004-1006
|
artikel
|
| 9 |
CLEC12A and CD33 coexpression as a preferential target for pediatric AML combinatorial immunotherapy
|
Willier, Semjon
|
|
|
137 |
8 |
p. 1037-1049
|
artikel
|
| 10 |
CNS relapse in DLBCL: a calculable risk?
|
Illerhaus, Gerald
|
|
|
137 |
8 |
p. 1011-1012
|
artikel
|
| 11 |
Editorial Board
|
|
|
|
137 |
8 |
p. i
|
artikel
|
| 12 |
Genomic subtypes may predict the risk of central nervous system recurrence in diffuse large B-cell lymphoma
|
Ollila, Thomas A.
|
|
|
137 |
8 |
p. 1120-1124
|
artikel
|
| 13 |
Getting under the skin: a new route for factor VIII?
|
McKinnon, Thomas A.J.
|
|
|
137 |
8 |
p. 1007-1008
|
artikel
|
| 14 |
Heat shock factor 1 (HSF1-pSer326) predicts response to bortezomib-containing chemotherapy in pediatric AML: a COG report
|
Hoff, Fieke W.
|
|
|
137 |
8 |
p. 1050-1060
|
artikel
|
| 15 |
Kundumani-Sridharan V, Niu J, Wang D, et al. 15(S)-hydroxyeicosatetraenoic acid–induced angiogenesis requires Src-mediated Egr-1–dependent rapid induction of FGF-2 expression. Blood. 2010;115(10):2105-2116.
|
|
|
|
137 |
8 |
p. 1131
|
artikel
|
| 16 |
Layered immunity of the developing thymus
|
López, Diego A.
|
|
|
137 |
8 |
p. 1003-1004
|
artikel
|
| 17 |
Long-term follow-up of lenalidomide and rituximab as initial treatment of follicular lymphoma
|
Strati, Paolo
|
|
|
137 |
8 |
p. 1124-1129
|
artikel
|
| 18 |
Neutrophil extracellular traps promote fibrous vascular occlusions in chronic thrombosis
|
Sharma, Smriti
|
|
|
137 |
8 |
p. 1104-1116
|
artikel
|
| 19 |
New hope offered to reduce GVHD
|
Zhang, Yi
|
|
|
137 |
8 |
p. 1010-1011
|
artikel
|
| 20 |
Preleukemic and leukemic evolution at the stem cell level
|
Stauber, Jacob
|
|
|
137 |
8 |
p. 1013-1018
|
artikel
|
| 21 |
Recombinant VWF fragments improve bioavailability of subcutaneous factor VIII in hemophilia A mice
|
Vollack-Hesse, Nadine
|
|
|
137 |
8 |
p. 1072-1081
|
artikel
|
| 22 |
Repurposing a novel anti-cancer RXR agonist to attenuate murine acute GVHD and maintain graft-versus-leukemia responses
|
Thangavelu, Govindarajan
|
|
|
137 |
8 |
p. 1090-1103
|
artikel
|
| 23 |
Trotman J, Opat S, Gottlieb D, et al. Zanubrutinib for the treatment of patients with Waldenström macroglobulinemia: 3 years of follow-up. Blood. 2020;136(18):2027–2037.
|
|
|
|
137 |
8 |
p. 1131
|
artikel
|
| 24 |
Venetoclax and ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia
|
Niemann, Carsten U.
|
|
|
137 |
8 |
p. 1117-1120
|
artikel
|
Tijdschrift beschrijving